ClinicalTrials.gg
Enrolling by invitationNCT06342999Updated May 1, 2026

Fetal Aortic Valvuloplasty for Evolving Hypoplastic Left Heart Syndrome

An interventional study of Fetal Aortic Valvuloplasty Procedure and Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter in Hypoplastic Left Heart Syndrome, sponsored by Mauro H. Schenone. Enrolling by invitation at 1 site in United States. Open to female participants aged Up to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Mauro H. Schenone · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
Up to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States — 6 open to participants now, 10 under way, 1 of them phase 3. Hypoplastic Left Heart Syndrome · United States.

Planned enrollment
5th of 26
80 · median 30
Started
2027
the only one that year
No phase
8 of 44
1 open now
Registered
41st of 44
by date

Among the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, this one is the 5th largest by planned enrollment of the 26 interventional ones that give a count, is the only one that started in 2027, is one of 8 with no phase, and was the 41st registered.

Hypoplastic Left Heart Syndrome

67 studies on the registry are indexed under Hypoplastic Left Heart Syndrome; 12 are open to participants now.

Browse Hypoplastic Left Heart Syndrome studies →

Open to participants now

6 of the 44 studies in Hypoplastic Left Heart Syndrome with a site in United States are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 9 Hypoplastic Left Heart Syndrome studies recruiting now, 3 set no upper age limit and 6 stop at 75 or younger; 9 take children under 18; none take healthy volunteers.

This study: Up to 45 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hypoplastic Left Heart Syndrome with a site in United States, or all of them as a file.
02

Study summary

The purpose of this research is to investigate the best way to manage evolving hypoplastic left heart syndrome (HLHS).

Read the detailed description

The condition occurs when part of the heart doesn't develop properly so the heart is not able to pump blood around the body effectively. Babies born with this condition require surgery and are often left with a lifelong heart disability. A number of babies with this condition will die during pregnancy or within the first year of life (approximately 10-40%). We are investigating a treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve. The aortic valve function is to allow easy flow from the heart to the body and prevent blood from returning to the heart (regurgitation). This is called fetal aortic valvuloplasty. A number of studies have shown promising results, including a higher of the baby surviving with both sides of the heart functioning (as opposed to only the right side), this may also lead to longer survival with a better quality of life. However, we do not have enough information to say this is always the best way to manage the condition. Currently, parents of babies with this condition, who meet certain eligibility criteria, are offered fetal aortic valvuloplasty during pregnancy. The alternative option is not to intervene during pregnancy but instead monitor the baby with regular ultrasounds. We call this conservative management.

03

Conditions studied

  • Hypoplastic Left Heart Syndrome
04

Who can participate

Ages eligible
Up to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Pregnant women 18-45 years of age.
  • Gestational age between 21 0/7 and 29 6/7 weeks of gestation
  • The mother must be healthy enough to undergo surgery.
  • The individual being enrolled must be able to provide .
  • Dominant cardiac defect is valvar
  • Evolving hypoplastic left heart syndrome defined as depressed left ventricle systolic and at least one of the following:

    • Retrograde flow in the transverse aortic arch
    • Two of the following: (1) left to right flow across the atrial septum (bulging of the septum left to right in cases of intact atrial septum); (2) monophasic mitral valve inflow; (3) bidirectional flow in the pulmonary veins.
  • Potential for a technically successful and postnatal biventricular outcome defined as left ventricle long axis Z-score equal or greater than -2 PLUS at least 4 of the following 5 criteria:

    • Left ventricle long axis Z-score more than zero
    • Left ventricle short axis Z-score more than zero
    • Aortic annulus Z-score more than -3.5
    • Mitral valve annulus Z-score more than -2
    • Left ventricle generating a maximal instantaneous gradient (MIG) equal or greater than 20 mmHg (or by mitral regurgitation jet greater than or equal to 20 mmHg).

Exclusion criteria

Exclusion Criteria

  • Patient is less than 18 years of age or more than 45 years of age.
  • to anesthesia or surgery
  • Preterm labor or cervical length \<20 mm at enrollment or uterine anomaly strongly predisposing to preterm delivery.
  • Other fetal anomalies that significantly impact fetal/neonatal survival (e.g., congenital diaphragmatic hernia, bilateral renal agenesis, etc.)
  • Fetal aneuploidy and pathogenic findings on Karyotype or Microarray that impact significantly the fetal/neonatal survival.
  • Cases with all the following criteria:

    • Left ventricle pressure ≤ 47 mmHg
    • MV dimension Z-score \< 0.1
    • MV inflow time Z-score \< -2
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Intervention Group: Fetal Aortic Valvuloplasty

    Women diagnosed with HLHS will undergo fetal aortic valvuloplasty between 21 and 29 weeks gestation.

    Procedure: Fetal Aortic Valvuloplasty Procedure · Device: Emerge Monorail and Over-The-Wire PTCA Dilatation Catheter · Device: Trek RX and Mini Trek RX Coronary Dilatation Catheter

  • No intervention
    Control Group: Expectant Management

    Women diagnosed with HLHS will undergo expectant management with postnatal surgery.

Interventions

  • ProcedureFetal Aortic Valvuloplasty Procedure

    Treatment given during pregnancy in which a balloon is used to increase the size of the baby's aortic valve in vitro.

  • DeviceEmerge Monorail and Over-The-Wire PTCA Dilatation Catheter

    Balloon Catheter

  • DeviceTrek RX and Mini Trek RX Coronary Dilatation Catheter

    Coronary Dilation Catheter

06

What researchers measure

Primary outcomes

  1. Number of cases in which the procedure was successful

    Procedure success defined as the aortic valve was crossed and the balloon inflated with clear evidence of improvement of blood flow through the aortic valve and or new aortic valve regurgitation

    Time frame: Baseline

  2. Number of cases in which a biventricular repair was achieved

    Time frame: Baseline

  3. Number cases with pulmonary hypertension

    Time frame: Baseline

Secondary outcomes

  1. Number of cases delivered prematurely

    Time frame: Baseline

  2. Number of cases with perinatal death

    Time frame: Baseline

  3. Number of maternal complications

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2027; primary completion for Jul 2036, 114 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2024
First posted
Apr 2, 2024
StartEst.
Jan 1, 2027
Primary completionEst.
Jul 2036
CompletionEst.
Jul 2036
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06342999
Lead sponsor
Mauro H. Schenone
Responsible party
Mauro H. Schenone (Regulatory Sponsor and Principal Investigator, Mayo Clinic) — Sponsor-investigator
First posted
Apr 2, 2024
Start date
Jan 1, 2027 (estimated)
Primary completion
Jul 2036 (estimated)
Completion
Jul 2036 (estimated)
Last update
May 1, 2026

Study contacts

Mauro Schenone, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion